8 research outputs found
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells
BRAF<sup>V600E</sup>-mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism
Abstract BRAF mutations occur early in serrated colorectal cancers, but their long-term influence on tissue homeostasis is poorly characterized. We investigated the impact of short-term (3 days) and long-term (6 months) expression of Braf V600E in the intestinal tissue of an inducible mouse model. We show that Braf V600E perturbs the homeostasis of intestinal epithelial cells, with impaired differentiation of enterocytes emerging after prolonged expression of the oncogene. Moreover, Braf V600E leads to a persistent transcriptional reprogramming with enrichment of numerous gene signatures indicative of proliferation and tumorigenesis, and signatures suggestive of metabolic rewiring. We focused on the top-ranking cholesterol biosynthesis signature and confirmed its increased expression in human serrated lesions. Functionally, the cholesterol lowering drug atorvastatin prevents the establishment of intestinal crypt hyperplasia in Braf V600E -mutant mice. Overall, our work unveils the long-term impact of Braf V600E expression in intestinal tissue and suggests that colorectal cancers with mutations in BRAF might be prevented by statins
Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma
Hypothesis: Asbestos-driven inflammation contributes to malignant pleural mesothelioma beyond the acquisition of rate-limiting mutations.
Methods: Genetically modified conditional allelic mice that were previously shown to develop mesothelioma in the absence of exposure to asbestos were induced with lentiviral vector expressing Cre recombinase with and without intrapleural injection of amosite asbestos and monitored until symptoms required euthanasia. Resulting tumours were examined histologically and by immunohistochemistry for expression of lineage markers and immune cell infiltration.
Results: Injection of asbestos dramatically accelerated disease onset and end-stage tumour burden. Tumours developed in the presence of asbestos showed increased macrophage infiltration. Pharmacological suppression of macrophages in mice with established tumours failed to extend survival or to enhance response to chemotherapy.
Conclusion: Asbestos-driven inflammation contributes to the severity of mesothelioma beyond the acquisition of rate-limiting mutations, however, targeted suppression of macrophages in established epithelioid mesothelioma showed no therapeutic benefit
The pathogenesis of mesothelioma is driven by a dysregulated translatome.
Funder: Department of HealthMalignant mesothelioma (MpM) is an aggressive, invariably fatal tumour that is causally linked with asbestos exposure. The disease primarily results from loss of tumour suppressor gene function and there are no 'druggable' driver oncogenes associated with MpM. To identify opportunities for management of this disease we have carried out polysome profiling to define the MpM translatome. We show that in MpM there is a selective increase in the translation of mRNAs encoding proteins required for ribosome assembly and mitochondrial biogenesis. This results in an enhanced rate of mRNA translation, abnormal mitochondrial morphology and oxygen consumption, and a reprogramming of metabolic outputs. These alterations delimit the cellular capacity for protein biosynthesis, accelerate growth and drive disease progression. Importantly, we show that inhibition of mRNA translation, particularly through combined pharmacological targeting of mTORC1 and 2, reverses these changes and inhibits malignant cell growth in vitro and in ex-vivo tumour tissue from patients with end-stage disease. Critically, we show that these pharmacological interventions prolong survival in animal models of asbestos-induced mesothelioma, providing the basis for a targeted, viable therapeutic option for patients with this incurable disease
Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma
Hypothesis: Asbestos-driven inflammation contributes to malignant pleural mesothelioma beyond the acquisition of rate-limiting mutations.Methods: Genetically modified conditional allelic mice that were previously shown to develop mesothelioma in the absence of exposure to asbestos were induced with lentiviral vector expressing Cre recombinase with and without intrapleural injection of amosite asbestos and monitored until symptoms required euthanasia. Resulting tumours were examined histologically and by immunohistochemistry for expression of lineage markers and immune cell infiltration.Results: Injection of asbestos dramatically accelerated disease onset and end-stage tumour burden. Tumours developed in the presence of asbestos showed increased macrophage infiltration. Pharmacological suppression of macrophages in mice with established tumours failed to extend survival or to enhance response to chemotherapy.Conclusion: Asbestos-driven inflammation contributes to the severity of mesothelioma beyond the acquisition of rate-limiting mutations, however, targeted suppression of macrophages in established epithelioid mesothelioma showed no therapeutic benefit
Investigation of Crosstalk Between GSK3 and the MAPK Pathway in V600EBRAF-Driven Colorectal Cancer
Colorectal cancer (CRC) is the third most prevalent cancer in advanced countries which mostly falls within the traditional class involving APC mutation. However, a recently classified V600EBRAF-driven class, sessile serrated CRCs (SSCRCs) was discovered to develop in the proximal colon. SSCRCs often evade detection because of their location and flat pale appearance. They have poor prognosis and are resistant to BRAF inhibition – necessitating the development of novel therapies for this devastating disease affecting~3000 people in the UK each year. A greater understanding of disease initiation and progression is needed for this purpose. A conditional, Cre-regulated, V600EBraf (BrafLSL-V600E/WT; Villin-CreERT (BVE/Cre)) knockin mouse model was therefore characterized. We show that initiation and progression of tumour development, from hyperplastic crypts to serrated adenomas and carcinomas, is similar to that reported in humans. A 3 day V600EBRaf expression results in the formation of hyperplastic crypts, which is surprisingly not associated with activation of the downstream MAPK pathway, and is not reversed by treating mice with MEK inhibitors. Instead, gene expression profiling shows upregulation of negative regulators of the MAPK pathway, a subset of Wnt pathway target genes, and genes involved in cholesterol biosynthesis and glycolysis, possibly accounting for the effect on crypt hyperplasia.
GSK3 phosphorylation role in V600EBRAF effects were investigated by intercrossing BVE mice with Gsk3a/b S9A/S21A mice. The combined mutant showed increased early-stage crypt elongation – suggesting GSK3 phosphorylation suppresses V600EBRAF-driven tumour initiation. Consistently, these mice demonstrated increased tumour burden at later stages, with no differences in tumour stage. Gene expression profiling shows this suppressive effect of GSK3 phosphorylation is most likely due to suppression of a subset of MAPK target genes. Altogether, these results provide novel insight into the role of V600EBraf at early stages of serrated CRC neoplasia
Recommended from our members
Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma.
Peer reviewed: TrueAcknowledgements: We wish to thank Prof. Anton Berns (NKI) for generously providing the CNP mice used in this study and Seth Coffelt (University of Glasgow & CRUK Glasgow Cancer Centre) for extensive discussions and scientific insights. Special thanks to all the staff at the CRUK Beatson Biological Services Unit and Histology core facility for technical support and to Catherine Winchester for critical editing. This article was submitted as a preprint to BioRxiv as Farahmand et al. (2020).Hypothesis: Asbestos-driven inflammation contributes to malignant pleural mesothelioma beyond the acquisition of rate-limiting mutations. Methods: Genetically modified conditional allelic mice that were previously shown to develop mesothelioma in the absence of exposure to asbestos were induced with lentiviral vector expressing Cre recombinase with and without intrapleural injection of amosite asbestos and monitored until symptoms required euthanasia. Resulting tumours were examined histologically and by immunohistochemistry for expression of lineage markers and immune cell infiltration. Results: Injection of asbestos dramatically accelerated disease onset and end-stage tumour burden. Tumours developed in the presence of asbestos showed increased macrophage infiltration. Pharmacological suppression of macrophages in mice with established tumours failed to extend survival or to enhance response to chemotherapy. Conclusion: Asbestos-driven inflammation contributes to the severity of mesothelioma beyond the acquisition of rate-limiting mutations, however, targeted suppression of macrophages in established epithelioid mesothelioma showed no therapeutic benefit
Recommended from our members
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells.
Mesothelioma is an aggressive cancer of the mesothelial layer associated with an extensive fibrotic response. The latter is in large part mediated by cancer-associated fibroblasts which mediate tumour progression and poor prognosis. However, understanding of the crosstalk between cancer cells and fibroblasts in this disease is mostly lacking. Here, using co-cultures of patient-derived mesothelioma cell lines and lung fibroblasts, we demonstrate that fibroblast activation is a self-propagated process producing a fibrotic extracellular matrix (ECM) and triggering drug resistance in mesothelioma cells. Following characterisation of mesothelioma cells/fibroblasts signalling crosstalk, we identify several FDA-approved targeted therapies as far more potent than standard-of-care Cisplatin/Pemetrexed in ECM-embedded co-culture spheroid models. In particular, the SRC family kinase inhibitor, Saracatinib, extends overall survival well beyond standard-of-care in a mesothelioma genetically-engineered mouse model. In short, we lay the foundation for the rational design of novel therapeutic strategies targeting mesothelioma/fibroblast communication for the treatment of mesothelioma patients